10.6084/m9.figshare.7145810.v1
Bosschieter J.
Bosschieter
J.
Nieuwenhuijzen J.A.
Nieuwenhuijzen
J.A.
Hentschel A.
Hentschel
A.
Vis A.N.
Vis
A.N.
Lissenberg-Witte B.I.
Lissenberg-Witte
B.I.
denOtter W.
denOtter
W.
vanMoorselaar R.J.A.
vanMoorselaar
R.J.A.
Supplementary Material for: Value of a Marker Lesion in Non-Muscle-Invasive Bladder Cancer Patients Treated with Interleukin-2 Instillations: A Randomized Controlled Multicentre Trial
Karger Publishers
2018
Urinary bladder neoplasms
Immunotherapy
Interleukin-2
Instillation
Marker tumour
2018-09-28 08:10:38
Dataset
https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Value_of_a_Marker_Lesion_in_Non-Muscle-Invasive_Bladder_Cancer_Patients_Treated_with_Interleukin-2_Instillations_A_Randomized_Controlled_Multicentre_Trial/7145810
<b><i>Purpose:</i></b> To compare the effect of intravesical interleukin-2 (IL-2) instillations with and without a marker lesion on time to recurrence (TTR) in non-muscle-invasive bladder cancer (NMIBC) patients. <b><i>Methods:</i></b> A prospective randomized, controlled trial was conducted. Patients with multiple non-muscle-invasive tumours were randomized for a complete or incomplete transurethral resection (TURBT), followed by 3 IL-2 instillations. The primary end point was TTR. <b><i>Results:</i></b> These are the results of an interim analysis, which was performed due to slow accrual after which the study was closed prematurely. Twenty-eight patients were randomized of which 17 were eligible on an intention-to-treat basis. Median TTR or last follow-up was 3 months (interquartile range [IQR] 3–10 months) for the complete and 4 months (IQR 3–8 months) for the incomplete TURBT group. The TTR between the 2 groups did not differ significantly (log-rank, <i>p</i> = 0.54). <b><i>Conclusions:</i></b> These data do not support the hypothesis that a marker lesion enhances the therapeutic effect of IL-2 instillations in patients with NMIBC.